window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'UA-108383172-1');

Novigenix Receives Reimbursement Coverage for Colox® in Switzerland

By |2019-10-09T09:09:47+02:009 October 2019|Communiqué de presse, Medical information, News Novigenix|

First liquid biopsy test reimbursed in Switzerland for colon cancer screening through private outpatient supplementary insurance product offered by Helsana LAUSANNE, SWITZERLAND - 07:00 CET, October  9, 2019  - Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine. today announced that Helsana, the leading health insurance

Novigenix’s New Early Colon Cancer Detection Blood Test Demonstrates Positive Results

By |2019-09-30T10:26:27+02:0030 September 2019|Communiqué de presse, News Novigenix|

Data on test’s newly discovered blood signature presented at ESMO 2019 LAUSANNE, SWITZERLAND - 07:00 CET, September 30, 2019 - Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine, today announced promising data from a study of a new Immuno-Transcriptomic signature for early detection of colorectal

Novigenix and BioLizard Sign Collaboration Agreement for Development of NGS Based Diagnostic Algorithm

By |2019-09-19T10:08:45+02:0019 September 2019|Communiqué de presse, News Novigenix|

AI-based Diagnostic Algorithm for Colon Cancer test on NGS platform LAUSANNE, SWITZERLAND - 07:00 CET, September 19, 2019 - Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine, today announced a collaboration agreement with BioLizard, an innovative bioinformatics company that aims to solve the most challenging

Novigenix to Present Data on New Molecular Signature for Early Detection of Colon Cancer at ESMO 2019

By |2019-09-11T14:34:45+02:0010 September 2019|Communiqué de presse, News Novigenix|

Company Launches New Website to Enhance New Strategy Company to present at the Convergence of Oncology meeting in Lausanne LAUSANNE, SWITZERLAND - 07:00 CET, September 10, 2019 - Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine, today announced the discovery of a new molecular signature

Novigenix Strengthens Board with Appointment of Francois Martelet, M.D. Non-Executive Director

By |2019-08-23T17:21:16+02:0018 June 2019|Communiqué de presse, News Novigenix|

LAUSANNE, SWITZERLAND - 07:00 CET, June 18, 2019 - Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes products for early cancer detection and precision medicine today announced the appointment of Francois Martelet, M.D. to its Board of Directors as a non-executive director. Dr. Martelet has over 25 years’ experience at both corporate and operational

Novigenix Appoints Dr. Jan Groen as CEO to Lead Expansion to Multi-Product Cancer Diagnostic Platform Company

By |2019-05-13T13:36:00+02:0013 May 2019|Communiqué de presse, News Novigenix|

ImmunoTranscriptomic platform combines identification of immune cell mRNA signatures with AI for early cancer detection   LAUSANNE, SWITZERLAND - 07:00 CET, May 13, 2019 - Novigenix SA, a leading ImmunoTranscriptomics company that develops and commercializes products for early cancer detection and precision medicine today announced the appointment of Dr. Jan Groen to the position of Chief

Novigenix Signs Distribution Agreement with Dr Risch Medical Laboratory to Access Swiss German Market for Colox®, its blood based colorectal cancer test

By |2018-04-04T15:12:36+02:0015 March 2017|Communiqué de presse|

Agreement significantly increases access to Colox® in Switzerland and Liechtenstein LAUSANNE, Switzerland, March 15, 2017 – Novigenix SA today announced a commercialization agreement with Dr Risch Medical Laboratory for Colox, its blood test for the early detection of colorectal cancer (CRC). Dr Risch is a successful and science-driven clinical laboratory organization with a strong foothold

Novigenix publishes multi-center study of Colox® in Clinical Cancer Research

By |2018-04-04T14:59:23+02:009 May 2016|Communiqué de presse|

Data validate blood-based test’s ability to detect colorectal cancer early and reliably LAUSANNE, Switzerland, May 9, 2015 – Novigenix SA today announced the publication of a clinical validation study of Colox in the highly ranked journal Clinical Cancer Research. Colox is a blood test based on a 29-gene host immune response panel in combination with

Novigenix acquires blood-based molecular diagnostics test Colox® and prepares its further commercial rollout in Switzerland and Europe to improve the early detection of colorectal cancer

By |2018-04-04T15:19:05+02:0012 February 2015|Communiqué de presse|

LAUSANNE, Switzerland, February 12, 2015 – Molecular diagnostics company Novigenix SA announced today it acquired Colox®, a new molecular blood test for the detection of colorectal cancer and pre-cancerous lesions (adenomatous polyps). Colox has been approved for sale in Europe, and has been launched commercially in Switzerland. Novigenix aims to increase the availability of Colox

Go to Top